



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: September 25, 2024

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 532989	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051. Scrip Code: BAFNAPH
---	--

Dear Sir/Madam,

**Subject: Disclosure Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 -
Re-appointment of Ms. S Hemalatha as Whole Time Director of the Company**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, We wish to inform you that the Members in the 29th Annual General Meeting (AGM) held on September 25, 2024, inter-alia, approved, ratified and confirmed the re-appointment of Ms. Shanmugam Hemalatha (DIN: 02714329) as the Whole-time Director of the Company for a period of 5 (Five) years w.e.f September 10, 2023.

The disclosure as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided in **Annexure-I**.

We request you take the above information on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Mohanachandran A
Company Secretary

Enclosed: As Above



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Annexure - I

Disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as under:

Sl. No.	Particulars	Description
1	Name of Director	Ms. Shanmugam Hemalatha
2	DIN	02714329
3	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-Appointment as Whole-Time Director of the Company.
4	Date of re-appointment	September 10, 2023.
5	Terms & Conditions of Appointment	Ms. Shanmugam Hemalatha, is re-appointed as Whole-Time Director of the Company, for a period of Five (5) Years with effect from September 10, 2023 to September 09, 2028, not liable to retire by rotation
6	Brief Profile	Ms. Shanmugam Hemalatha has more than two decades of experience in the pharmaceutical industry. She oversees commercial operations and plays a key role in strategic planning and financial oversight. Throughout her career, she has accumulated extensive experience in various roles within the company.
7	Disclosure of relationships between directors	Ms. Shanmugam Hemalatha is not related to any Director of the Company.
8	Remarks	The Members in the 29 th AGM held on September 25, 2024, approved, ratified and confirmed the re-appointment of Ms. Shanmugam Hemalatha (DIN: 02714329) as the Whole-time Director of the Company.